Fifth Third Bancorp Takes $27,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Fifth Third Bancorp purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating) during the third quarter, HoldingsChannel reports. The institutional investor purchased 4,569 shares of the biopharmaceutical company’s stock, valued at approximately $27,000.

Other hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP acquired a new stake in shares of TG Therapeutics in the 2nd quarter valued at approximately $403,000. Occudo Quantitative Strategies LP bought a new position in TG Therapeutics in the 2nd quarter valued at approximately $2,412,000. Liberty One Investment Management LLC raised its holdings in TG Therapeutics by 3,697.6% in the 2nd quarter. Liberty One Investment Management LLC now owns 4,709 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 4,585 shares during the last quarter. Delphia USA Inc. bought a new position in TG Therapeutics in the 2nd quarter valued at approximately $55,000. Finally, Commonwealth Equity Services LLC raised its holdings in TG Therapeutics by 678.8% in the 2nd quarter. Commonwealth Equity Services LLC now owns 111,739 shares of the biopharmaceutical company’s stock valued at $474,000 after buying an additional 97,391 shares during the last quarter. 68.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at TG Therapeutics

In related news, Director Yann Echelard acquired 9,000 shares of TG Therapeutics stock in a transaction dated Friday, January 6th. The stock was bought at an average price of $10.64 per share, with a total value of $95,760.00. Following the transaction, the director now directly owns 201,848 shares in the company, valued at approximately $2,147,662.72. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In related news, Director Yann Echelard acquired 9,000 shares of TG Therapeutics stock in a transaction dated Friday, January 6th. The stock was bought at an average price of $10.64 per share, with a total value of $95,760.00. Following the transaction, the director now directly owns 201,848 shares in the company, valued at approximately $2,147,662.72. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Laurence N. Charney sold 30,000 shares of the firm’s stock in a transaction that occurred on Wednesday, January 4th. The stock was sold at an average price of $11.10, for a total transaction of $333,000.00. Following the sale, the director now directly owns 234,729 shares of the company’s stock, valued at approximately $2,605,491.90. The disclosure for this sale can be found here. Insiders own 8.60% of the company’s stock.

TG Therapeutics Stock Up 3.3 %

TG Therapeutics stock opened at $13.63 on Friday. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -7.70 and a beta of 2.05. TG Therapeutics, Inc. has a 52-week low of $3.48 and a 52-week high of $15.85. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.02 and a current ratio of 5.02. The firm has a 50 day moving average price of $9.01 and a two-hundred day moving average price of $7.22.

TG Therapeutics (NASDAQ:TGTXGet Rating) last announced its quarterly earnings data on Thursday, November 10th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.07. The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $3.37 million. TG Therapeutics had a negative net margin of 4,749.83% and a negative return on equity of 149.86%. Equities analysts predict that TG Therapeutics, Inc. will post -1.33 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on TGTX shares. Evercore ISI raised their price objective on shares of TG Therapeutics from $11.00 to $16.00 and gave the company an “outperform” rating in a report on Friday, December 30th. StockNews.com started coverage on shares of TG Therapeutics in a report on Wednesday, October 12th. They issued a “sell” rating for the company. Bank of America raised their price target on shares of TG Therapeutics from $5.00 to $6.00 and gave the stock an “underperform” rating in a report on Thursday, December 29th. The Goldman Sachs Group raised their price target on shares of TG Therapeutics from $4.00 to $6.00 and gave the stock a “sell” rating in a report on Friday, December 30th. Finally, B. Riley raised their price target on shares of TG Therapeutics from $17.00 to $23.00 and gave the stock a “buy” rating in a report on Friday, December 30th. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $15.00.

About TG Therapeutics

(Get Rating)

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma.

See Also

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTXGet Rating).

Institutional Ownership by Quarter for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.